| 英文名稱 | Wilfordine |
|---|---|
| 中文名稱 | 雷公藤堿/雷公藤定堿 |
| CAS號 | 37239-51-3 |
| 分子式 | C43H49NO19 |
| 分子量 | 883.84 |
| 外觀 | |
| 沸點 | 895.5±65.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 11.63±0.70 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Wilfordine |
|---|---|
| 中文名稱 | 雷公藤堿/雷公藤定堿 |
| CAS號 | 37239-51-3 |
| 分子式 | C43H49NO19 |
| 分子量 | 883.84 |
| 外觀 | |
| 沸點 | 895.5±65.0 °C | Condition: Press: 760 Torr |
| 酸度系數pKa | 11.63±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0001414
中文名稱：雷公藤堿
中文別名：雷公藤定堿
英文名稱：Wilfordine
英文別名：Evonimine, 8-(acetyloxy)-O2-benzoyl-O2-deacetyl-8-deoxo-26-hydroxy-, (8α)-;Wilfordine (8CI);(8R,9R,10R,11S,12S,13R,14R,15S,21S,22S,23R)-10,13,22,23-Tetrakis(acetyloxy)-12-[(acetyloxy)methyl]-14-(benzoyloxy)-7,8,9,10,12,13,14,15,19,20-decahydro-18,21-dihydroxy-8,18,21-trimethyl-8,11-epoxy-9,12-ethano-11,15-methano-5H,11H-[1,9]dioxacyclooctadecino[4,3-b]pyridine-5,17(18H)-dione;8,11-Epoxy-9,12-ethano-11,15-methano-5H,11H-[1,9]dioxacyclooctadecino[4,3-b]pyridine-5,17-dione, 10,13,22,23-tetrakis(acetyloxy)-12-[(acetyloxy)methyl]-14-(benzoyloxy)-7,8,9,10,12,13,14,15,17,18,19,20-dodecahydro-18,21-dihydroxy-8,18,21-trimethyl-, (8R,9R,10R,11S,12S,13R,14R,15S,21S,22S,23R)-[partial]-;Wilfordin;Wtlfordine;
分子式：C43H49NO19
分子量：883.84
CAS號：37239-51-3
純度：HPLC≥98%
沸點：895.5±65.0 °C | Condition: Press: 760 Torr
密度：1.44±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數：11.63±0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規格：5mg10mg20mg50mg100mg500mg1g2g等應客戶需求包裝
供應單位：四川省維克奇生物科技有限公司
供應電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關注！ 新批次有現貨，歡迎咨詢。
| Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin-Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity. | ||
| 來源：SCI：Frontiers in Pharmacology | 作者：Wei Wu | 備注：影響因子：5.988 |
| 引用描述 | ||
TPL (Lot: 111,567–202,005) and irbesartan (as the IS for the MS/MS determination, Lot: 100,607–201,804) reference substances (content >99%) were obtained from National Institute for Food and Drug Control (Beijing, China). WA (Lot: wkq20040901), WFG (Lot: wkq20040804), WFT (Lot: wkq20040203), WFD (Lot: wkq20040702), and WFR (Lot: wkq20040205) reference substances (content >98%) were purchased from Sichuan Weikeqi Biological Technology Co., Ltd. (Sichuan, China). Adriamycin (ADR) hydrochloride for injection (Lot: 2007E1) was provided by Shenzhen Main Luck Pharmaceuticals Inc. (Shenzhen, China). | ||
| Wilforine, the Q-marker and PK-maker of Tripterygium glycosides tablet: Based on preparation quantitative analysis and PK-PD study | ||
| 來源：SCI：PHYTOMEDICINE | 作者：Xue Gao | 備注：影響因子：3.61 |
| 引用描述 | ||
Wilfortrine (NO. 151128), wilforine (NO. 151218), wilforgine (NO. 150922), and wilfordine (NO. 160127) reference substances (purity? > 98%) were all purchased from Sichuan Weikeqi Biological Technology Co., Ltd., tripterygium glycosides tablet samples were purchased from local pharmaceutical stores (Tianjin, China), which were produced by four manufactures (De-en De (DND) | ||
